Stock Analysis
Heidelberg Pharma First Quarter 2024 Earnings: €0.10 loss per share (vs €0.14 loss in 1Q 2023)
Heidelberg Pharma (ETR:HPHA) First Quarter 2024 Results
Key Financial Results
- Revenue: €1.86m (down 10% from 1Q 2023).
- Net loss: €4.49m (loss narrowed by 32% from 1Q 2023).
- €0.10 loss per share (improved from €0.14 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Heidelberg Pharma Earnings Insights
Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe.
Performance of the market in Germany.
The company's shares are up 2.4% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for Heidelberg Pharma that you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Heidelberg Pharma is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:HPHA
Heidelberg Pharma
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally.
Mediocre balance sheet with limited growth.